Arvinas (ARVN) Insider Smaldone Alsup Laurie Buys 15,527 Shares

On June 24, 2026, Laurie Smaldone Alsup, an insider at Arvinas, Inc., increased her stake in the company by purchasing 15,527 shares. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Arvinas, Inc.

Several insiders at Arvinas, Inc. made purchases on June 24, 2026. Laurie Smaldone Alsup bought 15,527 shares. Other insiders, including Linda Bain and Edward Moore Jr., also increased their holdings with similar share purchases, indicating internal confidence in the company's prospects.

Other Institutional Activity in Arvinas, Inc.

Institutional investors have been adjusting their positions in Arvinas, Inc. BlackRock, Inc. reduced its holdings by 524,917 shares, leaving it with 6,797,584 shares worth around $72.1 million. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 3,889,628 shares valued at approximately $41.2 million. D. E. Shaw & Co., Inc. trimmed its stake by 50,634 shares, holding 3,638,567 shares valued at about $38.6 million.

Arvinas, Inc. Stock Down 3.5%

Shares of NasdaqGS:ARVN traded at $8.03 on Saturday. Arvinas, Inc. has a market capitalization of $518.1 million. The company, which is not currently profitable, has a forward P/E ratio of -2.33 and a beta of 1.745, indicating some volatility. The stock has seen a 52-week low of $6.06 and a high of $14.51, with a 50-day moving average of $9.08 and a 200-day moving average of $10.67.

Recent Earnings

Arvinas, Inc. reported revenues of $89.4 million with a negative revenue growth of 91.7%. The company's net margin stood at -247.5%, and return on equity was -42.3%. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Arvinas, Inc. On June 3, 2026, Stephens & Co. reiterated a 'buy' rating with an $18.00 price target. Barclays and BTIG also maintained their 'buy' ratings with targets of $20.00 and $18.00, respectively. The consensus among 15 analysts is a 'buy' recommendation, with a target mean price of $14.8.

About Arvinas, Inc.

Arvinas, Inc., based in New Haven, Connecticut, is a biotechnology company focused on developing therapies that degrade disease-causing proteins. It employs 246 people and is led by CEO Dr. Randy Teel. The company works on various clinical programs, including treatments for neurodegenerative diseases and cancers, and collaborates with major firms like Pfizer and Genentech.

Bottom Line

Insider buying at Arvinas, Inc. could signal confidence in the company's future from those within. The stock's performance reflects its current market challenges, but ongoing institutional interest and analyst ratings suggest a watchful eye on its potential. Remember, insider transactions and analyst ratings are backward-looking and should be considered as part of a broader investment analysis.